REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinson's disease

Journal of Neuroscience Research

Volumn 91, Issue 11, 2013, Pages 1508-1516

  Dos Santos, Ana Carolina D ^a   Castro, Marcela Alexandra V ^a   Jose, Elis Angela K ^a   Delattre, Ana Márcia ^a   Dombrowski, Patrícia A ^a   Da Cunha, Claudio ^a   Ferraz, Anete C ^a   Lima, Marcelo M S ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Dopamine; Intranigral; Parkinson's disease; REM sleep deprivation; Rotenone; Substantia nigra pars compacta

Indexed keywords

DOPAMINE; ROTENONE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; DOPAMINE RELEASE; MALE; MEMORY DISORDER; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; OBJECT RECOGNITION; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECOGNITION; REM SLEEP DEPRIVATION; STEREOTAXIC SURGERY; TURNOVER TIME;

DOPAMINE; INTRANIGRAL; PARKINSON'S DISEASE; REM SLEEP DEPRIVATION; ROTENONE; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; BEHAVIOR, ANIMAL; COGNITION; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENTRICULAR; LEARNING; MALE; MEMORY; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; ROTENONE; SLEEP DEPRIVATION; UNCOUPLING AGENTS;

EID: 84884713010     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23258     Document Type: Article

References (51)

1. Alam M, Schmidt WJ. 2004. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav Brain Res 153:439-446.
2. Albin RL, Koeppe RA, Chervin RD, Consens FB, Wernette K, Frey KA, Aldrich MS. 2000. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 55:1410-1412.
3. Andersen ML, Perry JC, Battisti MC, Calzavara MB, Costa JL, Neto ON, Frussa-Filho R, Tufik S. 2006. Association of paradoxical sleep deprivation and ecstasy (MDMA) enhances genital reflexes in male rats. Behav Brain Res 170:287-292.
4. Ariza D, Lima MM, Moreira CG, Dombrowski PA, Avila TV, Allemand A, Mendes DA, Da Cunha C, Vital MA. 2010. Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease. Neurochem Res 35:1620-1627.
5. Asikainen M, Toppila J, Alanko L, Ward DJ, Stenberg D, Porkka-Heiskanen T. 1997. Sleep deprivation increases brain serotonin turnover in the rat. Neuroreport 8:1577-1582.
6. Barbiero JK, Santiago RM, Lima MM, Ariza D, Morais LH, Andreatini R, Vital MA. 2010. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res (in press).
7. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, Ghorayeb I. 2009. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol 219:574-582.
8. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
9. Broadhurst PL. 1960. Experiments in psychogenetics. In: Einsenk HJ, ed. Experiments in personality. London: Routledge and Kegan Paul. p 52-71.
10. Chaudhuri KR. 2003. Nocturnal symptom complex in PD and its management. Neurology 61(Suppl 3):S17-S23.
11. Comella C. 2003. Sleep episodes in Parkinson's disease: more questions remain. Sleep Med 4:267-268.
12. Comella CL, Tanner CM, Ristanovic RK. 1993. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 34:710-714.
13. Dahan L, Astier B, Vautrelle N, Urbain N, Kocsis B, Chouvet G. 2007. Prominent burst firing of dopaminergic neurons in the ventral tegmental area during paradoxical sleep. Neuropsychopharmacology 32:1232-1241.
14. Dere E, Silva MA, Huston JP. 2004. Higher order memories for objects encountered in different spatio-temporal contexts in mice: evidence for episodic memory. Rev Neurosci 15:231-240.
15. Drolet RE, Cannon JR, Montero L, Greenamyre JT. 2009. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 36:96-102.
16. Dzirasa K, Ribeiro S, Costa R, Santos LM, Lin SC, Grosmark A, Sotnikova TD, Gainetdinov RR, Caron MG, Nicolelis MA. 2006. Dopaminergic control of sleep-wake states. J Neurosci 26:10577-10589.
17. Eisensehr I, Linke R, Tatsch K, Kharraz B, Gildehaus JF, Wetter CT, Trenkwalder C, Schwarz J, Noachtar S. 2003. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 26:507-512.
18. Ennaceur A, Delacour J. 1988. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31:47-59.
19. Ennaceur A, Michalikova S, Bradford A, Ahmed S. 2005. Detailed analysis of the behavior of Lister and Wistar rats in anxiety, object recognition and object location tasks. Behav Brain Res 159:247-266.
20. Fantini ML, Gagnon JF, Filipini D, Montplaisir J. 2003. The effects of pramipexole in REM sleep behavior disorder. Neurology 61:1418-1420.
21. Gagnon JF, Bedard MA, Fantini ML, Petit D, Panisset M, Rompre S, Carrier J, Montplaisir J. 2002. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 59:585-589.
22. Garcia-Borreguero D, Caminero AB, De La Llave Y, Larrosa O, Barrio S, Granizo JJ, Pareja JA. 2002. Decreased phasic EMG activity during rapid eye movement sleep in treatment-naive Parkinson's disease: effects of treatment with levodopa and progression of illness. Mov Disord 17:934-941.
23. Gilman S, Koeppe RA, Chervin RD, Consens FB, Little R, An H, Junck L, Heumann M. 2003. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 61:29-34.
24. Greenamyre JT, Betarbet R, Sherer TB. 2003. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Rel Disord 9(Suppl 2):S59-S64.
25. Hsieh PF, Chia LG, Ni DR, Cheng LJ, Ho YP, Tzeng SF, Chang MH, Hong JS. 2002. Behavior, neurochemistry and histology after intranigral lipopolysaccharide injection. Neuroreport 13:277-280.
26. Laloux C, Derambure P, Kreisler A, Houdayer E, Brueziere S, Bordet R, Destee A, Monaca C. 2008. MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations. Exp Brain Res 186:635-642.
27. Lena I, Parrot S, Deschaux O, Muffat-Joly S, Sauvinet V, Renaud B, Suaud-Chagny MF, Gottesmann C. 2005. Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J Neurosci Res 81:891-899.
28. Levey AI, Hersch SM, Rye DB. 1993. localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci U S A 90:8861-8865.
29. Lima MMS. 2013. Sleep disturbances in Parkinson's disease: the contribution of dopamine in REM sleep regulation. Sleep Med Rev (in press).
30. Lima MMS, Andersen ML, Reksidler AB, Vital MABF, Tufik S. 2007. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE 2:e513.
31. Lima MMS, Andersen ML, Reksidler AB, Silva A, Zager A, Zanata SM, Vital MA, Tufik S. 2008. Blockage of dopaminergic D2 receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation. Behav Brain Res 188:406-411.
32. Lima MM, Andersen ML, Reksidler AB, Ferraz AC, Vital MA, Tufik S. 2012a. Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion. CNS Neurol Disord Drug Targets 11:359-368.
33. Lima MM, Martins EF, Delattre AM, Proenca MB, Mori MA, Carabelli B, Ferraz AC. 2012b. Motor and non-motor features of Parkinson's disease-a review of clinical and experimental studies. CNS Neurol Disord Drug Targets 11:439-449.
34. Lima MMS, Andersen ML, Reksidler AB, Ferraz AC, Vital AM, Tufik S. 2012c. Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion. CNS Neurol Disord Drug Targets 11:359-368.
35. Machado RB, Hipolide DC, Benedito-Silva AA, Tufik S. 2004. Sleep deprivation induced by the modified multiple platform technique: quantification of sleep loss and recovery. Brain Res 1004:45-51.
36. Monaca C, Laloux C, Jacquesson JM, Gele P, Marechal X, Bordet R, Destee A, Derambure P. 2004. Vigilance states in a parkinsonian model, the MPTP mouse. Eur J Neurosci 20:2474-2478.
37. Moreira CG, Barbiero JK, Ariza D, Dombrowski PA, Sabioni P, Bortolanza M, Cunha CD, Vital MA, Lima MM. 2012. Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin. Neurotox Res 21:291-301.
38. Morris RG. 2001. Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci 356:1453-1465.
39. Nunes GP, Tufik S, Nobrega JN. 1994. Autoradiographic analysis of D1 and D2 dopaminergic receptors in rat brain after paradoxical sleep deprivation. Brain Res Bull 34:453-456.
40. Ozawa T, Yamada K, Ichitani Y. 2011. Long-term object location memory in rats: effects of sample phase and delay length in spontaneous place recognition test. Neurosci Lett 497:37-41.
41. Parkinson J. 1817. An essay on the shaking palsy. Sherwood NJ, editor. London: Sherwood.
42. Paxinos G, Watson C. 2005. The rat brain in stereotaxic coordinates, 5th ed. San Diego: Academic Press.
43. Porkka-Heiskanen T, Tuomisto L, Ylinen M, Stenberg D. 1994. The effect of REM sleep deprivation on histamine concentrations in different brain areas. Life Sci 54:1719-1726.
44. Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, Vital MA. 2010. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 34:1104-1114.
45. Saravanan KS, Sindhu KM, Mohanakumar KP. 2005. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 1049:147-155.
46. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. 1986. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 9:293-308.
47. Segura Aguilar J, Kostrzewa RM. 2004. Neurotoxins and neurotoxic species implicated in neurodegeneration. Neurotox Res 6:615-630.
48. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. 2003. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23:10756-10764.
49. Souchay C, Isingrini M, Gil R. 2006. Metamemory monitoring and Parkinson's disease. J Clin Exp Neuropsychol 28:618-630.
50. Tufik S, Lindsey CJ, Carlini EA. 1978. Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain? Pharmacology 16:98-105.
51. Verhave PS, Jongsma MJ, Van den Berg RM, Vis JC, Vanwersch RA, Smit AB, Van Someren EJ, Philippens IH. 2011. REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep 34:1119-1125.